A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
NCT ID: NCT03380780 Phase: PHASE1 Status: COMPLETED Enrollment: 16 Completion: 2018-09-18
Conditions
Healthy Volunteers, Hemophilia A
Interventions
Emicizumab
Summary
This single-center, open-label study will evaluate the pharmacokinetics, safety, and tolerability of emicizumab following a single subcutaneous (SC) administration to healthy Chinese subjects.
Primary Outcome
Maximum Observed Plasma Concentration (Cmax) of Emicizumab